知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.017 秒)

    OSTEOGENIC DIFFERENTIATION OF PREOSTEOBLASTIC CELLS
    2.
    发明申请
    OSTEOGENIC DIFFERENTIATION OF PREOSTEOBLASTIC CELLS 审中-公开
    预处理细胞的生物学分化

    公开(公告)号：US20080279832A1

    公开(公告)日：2008-11-13

    申请号：US12119288

    申请日：2008-05-12

    申请人： Kwan Hee LEE ,  Moon Jong Noh ,  Youngsuk Yi

    发明人： Kwan Hee LEE ,  Moon Jong Noh ,  Youngsuk Yi

    IPC分类号： A61K35/32 ,  A61P19/00

    CPC分类号： A61K35/32 ,  A61K38/1841 ,  A61K2300/00

    摘要： The application discloses a method for making bone at a bone defect site which includes generating a member of a transforming growth factor superfamily of proteins; generating a population of cultured connective tissue cells that may contain a vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and transferring the protein and the connective tissue cells of to the bone defect site, and allowing the bone defect site to make the bone.

    摘要翻译： 该申请公开了一种在骨缺损位点处制造骨的方法，其包括产生蛋白质的转化生长因子超家族的成员; 产生可包含编码基因的载体的培养的结缔组织细胞群，或不含任何编码基因的载体的培养的结缔组织细胞群; 并将蛋白质和结缔组织细胞转移到骨缺损部位，并允许骨缺损部位制成骨。

    Gene therapy using TGF-&bgr;
    4.
    发明授权
    Gene therapy using TGF-&bgr; 有权
    使用TGF-β的基因治疗

    公开(公告)号：US06797703B1

    公开(公告)日：2004-09-28

    申请号：US09702718

    申请日：2000-11-01

    申请人： Moon Jong Noh ,  Kyoung Ae Kang ,  Kwan Hee Lee

    发明人： Moon Jong Noh ,  Kyoung Ae Kang ,  Kwan Hee Lee

    IPC分类号： A61K3500

    CPC分类号： A61K38/1841 ,  A61K35/12 ,  A61K48/00 ,  C07K14/495

    摘要： The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factory-&bgr; (TGF-&bgr;) superfamily. TGF-&bgr; gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-&bgr; cDNA expression vectors into fibroblasts (NIH 3T3-TGF-&bgr;1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.

    摘要翻译： 本发明涉及使用属于转化生长工厂-β（TGF-β）超家族的成员的骨科疾病的细胞介导的基因治疗治疗。 证实了TGF-β基因治疗作为退行性关节炎的新治疗方法。 将TGF-βcDNA表达载体转染到成纤维细胞（NIH 3T3-TGF-β1）后，将细胞注射到兔子跟腱和膝关节中，人工制造软骨缺损。 进行Intratendinous注射以确定体内表达的最佳浓度。 进行部分缺陷软骨模型，以模拟膝关节退行性关节炎。 用细胞介导的基因治疗程序处理的部分软骨缺损被新形成的透明软骨覆盖，表明细胞存活并刺激了该区域的基质形成。 完全剥落的软骨区域被纤维胶原覆盖。

    Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-&bgr;-1
    6.
    发明授权
    Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-&bgr;-1 有权
    使用用编码TGF-β-1的载体转染的成纤维细胞在哺乳动物中产生软骨

    公开(公告)号：US06315992B1

    公开(公告)日：2001-11-13

    申请号：US09345415

    申请日：1999-06-30

    申请人： Moon Jong Noh ,  Kyoung Ae Kang ,  Kwan Hee Lee

    发明人： Moon Jong Noh ,  Kyoung Ae Kang ,  Kwan Hee Lee

    IPC分类号： A61K3500

    CPC分类号： A61K38/1841 ,  A61K35/12 ,  A61K48/00 ,  C07K14/495

    摘要： The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-&bgr; (TGF-&bgr;) superfamily. TGF-&bgr; gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-&bgr; cDNA expression vectors into fibroblasts (NIH 3T3-TGF-&bgr;1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.

    摘要翻译： 本发明涉及使用属于转化生长因子-β（TGF-β）超家族的成员的骨科疾病的细胞介导的基因治疗治疗。 证实了TGF-β基因治疗作为退行性关节炎的新治疗方法。 将TGF-βcDNA表达载体转染到成纤维细胞（NIH 3T3-TGF-β1）后，将细胞注射到兔子跟腱和膝关节中，人工制造软骨缺损。 进行Intratendinous注射以确定体内表达的最佳浓度。 进行部分缺陷软骨模型，以模拟膝关节退行性关节炎。 用细胞介导的基因治疗程序处理的部分软骨缺损被新形成的透明软骨覆盖，表明细胞存活并刺激了该区域的基质形成。 完全剥落的软骨区域被纤维胶原覆盖。

    Gene therapy using TGF-β
    7.
    发明授权
    Gene therapy using TGF-β 有权
    使用TGF-β的基因治疗

    公开(公告)号：US07338655B1

    公开(公告)日：2008-03-04

    申请号：US09707900

    申请日：2000-11-08

    申请人： Moon Jong Noh ,  Kyoung Ae Kang ,  Kwan Hee Lee

    发明人： Moon Jong Noh ,  Kyoung Ae Kang ,  Kwan Hee Lee

    IPC分类号： A01N65/00 ,  A01N63/00 ,  A01N43/04 ,  A61K31/70 ,  A61K48/00

    CPC分类号： A61K48/00 ,  A61K31/70 ,  A61K38/1841

    摘要： The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.

    摘要翻译： 本发明涉及使用属于转化生长因子-β（TGF-β）超家族的成员的骨科疾病的细胞介导的基因治疗治疗。 证实了TGF-β基因治疗作为退行性关节炎的新治疗方法。 将TGF-βcDNA表达载体转染到成纤维细胞（NIH 3T3-TGF-β1）后，将细胞注射到兔子跟腱和膝关节中，人工制造软骨缺损。 进行Intratendinous注射以确定体内表达的最佳浓度。 进行部分缺陷软骨模型，以模拟膝关节退行性关节炎。 用细胞介导的基因治疗程序处理的部分软骨缺损被新形成的透明软骨覆盖，表明细胞存活并刺激了该区域的基质形成。 完全剥落的软骨区域被纤维胶原覆盖。

    MIXED-CELL GENE THERAPY
    9.
    发明申请
    MIXED-CELL GENE THERAPY 审中-公开
    混合细胞基因治疗

    公开(公告)号：US20100330053A1

    公开(公告)日：2010-12-30

    申请号：US12882027

    申请日：2010-09-14

    申请人： Sun Uk SONG ,  Youngsuk Yi ,  Kwan Hee Lee ,  Moon Jong Noh

    发明人： Sun Uk SONG ,  Youngsuk Yi ,  Kwan Hee Lee ,  Moon Jong Noh

    IPC分类号： A61K48/00 ,  A61P19/02 ,  A61P19/00

    CPC分类号： C12N5/0656 ,  A61K35/12 ,  A61K35/32 ,  A61K35/33 ,  A61K48/00 ,  A61K48/0008 ,  C12N5/0655 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2502/13 ,  C12N2502/1317 ,  C12N2502/99 ,  C12N2510/02

    摘要： The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.

    摘要翻译： 本发明涉及一种混合细胞组合物，其通过提供用寻求表达的基因转染或转导的第一群哺乳动物细胞，以及第二组哺乳动物细胞，在靶位点产生治疗性蛋白质 被转染或转导的基因，其中哺乳动物细胞的第二群体的内源存在形式在靶位点减少，并且其中在靶位点由哺乳动物细胞的第一群体产生治疗性蛋白质刺激第二群体细胞 诱导治疗效果。

    Gene Therapy Using TGF-beta
    10.
    发明申请
    Gene Therapy Using TGF-beta 审中-公开
    使用TGF-β的基因治疗

    公开(公告)号：US20080226611A1

    公开(公告)日：2008-09-18

    申请号：US12014715

    申请日：2008-01-15

    申请人： Moon Jong NOH ,  Kyoung Ae Kang ,  Kwan Hee Lee

    发明人： Moon Jong NOH ,  Kyoung Ae Kang ,  Kwan Hee Lee

    IPC分类号： A61K48/00 ,  C12N5/10 ,  A61P19/02

    CPC分类号： A61K38/1841 ,  A61K35/12 ,  A61K38/1875 ,  A61K48/00 ,  C07K14/495

    摘要： The subject invention is related to a cell-mediated gene therapy treatment for orthopedic disease using a member belonging to the transforming growth factor-β (TGF-β) superfamily. TGF-β gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF-β cDNA expression vectors into fibroblasts (NIH 3T3-TGF-β1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performed to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.

    摘要翻译： 本发明涉及使用属于转化生长因子-β（TGF-β）超家族的成员的骨科疾病的细胞介导的基因治疗治疗。 证实了TGF-β基因治疗作为退行性关节炎的新治疗方法。 将TGF-βcDNA表达载体转染到成纤维细胞（NIH 3T3-TGF-β1）后，将细胞注射到兔子跟腱和膝关节中，人工制造软骨缺损。 进行Intratendinous注射以确定体内表达的最佳浓度。 进行部分缺陷软骨模型，以模拟膝关节退行性关节炎。 用细胞介导的基因治疗程序处理的部分软骨缺损被新形成的透明软骨覆盖，表明细胞存活并刺激了该区域的基质形成。 完全剥落的软骨区域被纤维胶原覆盖。